Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | NT5E | P21589 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140968 | 0.98 | TYMP (0.40) | TYMPADORA1NT5EADORA2AADORA2B | |
| SCHEMBL31359555 | 0.94 | TYMP (0.42) | TYMPADORA1NT5EADORA2AADORA2B | |
| SCHEMBL30141033 | 0.91 | TYMP (0.42) | TYMPADORA1NT5E | |
| SCHEMBL24191301 | 0.89 | ADORA1 (0.43) | TYMPADORA1NT5E | |
| SCHEMBL20691389 | 0.87 | TYMP (0.57) | TYMPADORA1 | |
| SCHEMBL2365653 | 0.87 | TYMP (0.42) | TYMPADORA1NT5E | |
| SCHEMBL30141043 | 0.86 | TYMP (0.38) | TYMPADORA1NT5EADORA2AADORA2B | |
| SCHEMBL29827283 | 0.85 | TYMP (0.39) | TYMP | |
| SCHEMBL16871812 | 0.85 | TYMP (0.39) | TYMPADORA1 | |
| SCHEMBL16871856 | 0.85 | TYMP (0.39) | TYMPADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | TYMP 76/4885ADORA1 107/4885NT5E 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.